2. Cell Cycle/DNA Damage Anti-infection Autophagy Apoptosis Metabolic Enzyme/Protease
  3. DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy Endogenous Metabolite Apoptosis Orthopoxvirus
  4. Cytarabine

Cytarabine  (Synonyms: Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Cat. No.: HY-13605 Purity: 99.98%
COA
SDS
Handling Instructions Technical Support

Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 147-94-4

사이즈 가격 재고 수량
100 mg 해외재고보유
500 mg 해외재고보유
1 g 해외재고보유
5 g   견적 받기  
10 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 95 publication(s) in Google Scholar

Other Forms of Cytarabine:

Cytarabine Related Antibodies

Top Publications Citing Use of Products

95 Publications Citing Use of MCE Cytarabine

Cell Proliferation/Viability Assay
WB

    Cytarabine purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305.  [Abstract]

    FKA (Flavokawain A; HY-N2420) decreases the viability in AML cell lines. MV4-11, MOLM-13, THP-1, and U937 cells were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 24 and 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605; 7.3 μg/mL) was used as a positive control.

    Cytarabine purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305.  [Abstract]

    FKA (Flavokawain A; HY-N2420) targets primary AML blasts. Samples from AML patients were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605) was used as a positive control. Data were shown as mean ± SD from at least three independent experiments.

    Cytarabine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Sep 27:101770.  [Abstract]

    Cell viability of WiT49-parental and WiT49-PRC-1 cells treated with cytarabine. IC50 is shown in the figure. The WiT49-PRC-1 cells are 100-fold more sensitive to cytarabine and 20-fold more sensitive to alisertib than the parental WiT49 cells.

    Cytarabine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839.  [Abstract]

    TF-1 clones are incubated with 2 µM Cytarabine (araC) for up to 10 or 12 h, and cleaved caspase-3 is detected by immunoblot analysis.

    Cytarabine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839.  [Abstract]

    TF-1 clones were incubated with 2 µM araC or 1 µM DNR for up to 10 or 12 h, respectively, and cleaved caspase-3 was detected by immunoblot analysis. GAPDH was used as loading control.

    View All DNA/RNA Synthesis Isoform Specific Products:

    View All Isoforms
    RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

    View All HSV Isoform Specific Products:

    View All Isoforms
    HSV-1 HSV-2 HSV

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Protocol

    • 순도&문서

    • References

    • 고객리뷰

    제품 설명

    Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.

    IC50 & Target[1]

    Microbial Metabolite

     

    DNA Polymerase

     

    HSV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    143B IC50
    2.06 3
    Compound: Cytarabine
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    143B IC50
    16.88 3
    Compound: Cytarabine
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    143B IC50
    2.06 3
    Compound: Cytarabine
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    143B IC50
    16.88 3
    Compound: Cytarabine
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    A-375 IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against A-375 cell line human melanoma
    Tested in vitro against A-375 cell line human melanoma
    		[PMID: 8277499]
    A-375 IC50
    >410 3
    Compound: ara-c
    Tested in vitro against A-375 cell line human melanoma
    Tested in vitro against A-375 cell line human melanoma
    		[PMID: 8277499]
    A549 GI50
    0.2 3
    Compound: Ara-C
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    A549 IC50
    202.57 3
    Compound: CAR
    Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 38516604]
    A549 IC50
    0.83 3
    Compound: ara-C
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    A549 IC50
    49.27 6
    Compound: CAR
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 35963130]
    A549 GI50
    0.2 3
    Compound: Ara-C
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    A549 IC50
    0.83 3
    Compound: ara-C
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    A549 IC50
    620 3
    Compound: cytarabine
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    		[PMID: 17419604]
    A549 IC50
    1.2 3
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    A549 IC50
    1.75 3
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    A549 IC50
    1.2 3
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    A549 IC50
    1.75 3
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    A549 IC50
    1.9 3
    Compound: 1, ara-C
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    		[PMID: 19691349]
    A549 IC50
    1.9 3
    Compound: 2, Ara-C
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 24956556]
    A549 IC50
    1.9 3
    Compound: 1, ara-C
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    		[PMID: 19691349]
    A549 IC50
    1.9 3
    Compound: 2, Ara-C
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 24956556]
    A549 IC50
    3.47 3
    Compound: ara-C
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    A549 IC50
    1.9 3
    Compound: AraC
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 38716896]
    AMML IC50
    2.3 3
    Compound: ara-C
    Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)
    Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)
    		[PMID: 3761322]
    A549 IC50
    202.57 3
    Compound: CAR
    Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 38516604]
    A549 IC50
    3.47 3
    Compound: ara-C
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    B16 IC50
    30.62 3
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    A549 IC50
    49.27 6
    Compound: CAR
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 35963130]
    B16 IC50
    49.22 3
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    A549 IC50
    620 3
    Compound: cytarabine
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    		[PMID: 17419604]
    B16 IC50
    0.24 6
    Compound: Ara-C
    In vitro inhibitory activity against Mouse melanoma (B16) cell line.
    In vitro inhibitory activity against Mouse melanoma (B16) cell line.
    		[PMID: 1995905]
    L1210 IC50
    0.4 1
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    		[PMID: 19674903]
    AMML IC50
    2.3 3
    Compound: ara-C
    Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)
    Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)
    		[PMID: 3761322]
    B16 IC50
    0.24 6
    Compound: Ara-C
    In vitro inhibitory activity against Mouse melanoma (B16) cell line.
    In vitro inhibitory activity against Mouse melanoma (B16) cell line.
    		[PMID: 1995905]
    BALL-1 GI50
    0.08 3
    Compound: Ara-C
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    Bel-7402 IC50
    34.2 3
    Compound: Ara-C
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    		[PMID: 20692841]
    B16 IC50
    30.62 3
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    B16 IC50
    49.22 3
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    Bone marrow cell GI50
    64.1 3
    Compound: Cytarabine
    Growth inhibition of human bone marrow cells
    Growth inhibition of human bone marrow cells
    		[PMID: 29995404]
    CAKI-1 IC50
    >5 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against renal CAKI-1 cells
    In vitro cytotoxicity was evaluated against renal CAKI-1 cells
    		[PMID: 10780904]
    CCRF S-180 ED50
    0.2 3
    Compound: ara-C
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    BALL-1 GI50
    0.08 3
    Compound: Ara-C
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    CCRF S-180 ED50
    0.2 3
    Compound: ara-C
    Effective dose to inhibit the replication of S180 cell line in vitro.
    Effective dose to inhibit the replication of S180 cell line in vitro.
    		[PMID: 1995894]
    CCRF S-180 IC50
    25.43 3
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    Bel-7402 IC50
    34.2 3
    Compound: Ara-C
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    		[PMID: 20692841]
    CCRF S-180 IC50
    40.33 3
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    Bone marrow cell GI50
    64.1 3
    Compound: Cytarabine
    Growth inhibition of human bone marrow cells
    Growth inhibition of human bone marrow cells
    		[PMID: 29995404]
    CCRF-CEM EC50
    0.00561 3
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CCRF-CEM EC50
    0.0228 3
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CAKI-1 IC50
    > 5 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against renal CAKI-1 cells
    In vitro cytotoxicity was evaluated against renal CAKI-1 cells
    		[PMID: 10780904]
    CCRF-CEM ED50
    0.006 3
    Compound: ara-C
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    CCRF-CEM ED50
    120 3
    Compound: ara-C
    Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)
    Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)
    		[PMID: 1652024]
    CCRF-CEM ED50
    0.005 3
    Compound: ara-C
    Inhibit the replication of CCRF-CEM cell line in vitro.
    Inhibit the replication of CCRF-CEM cell line in vitro.
    		[PMID: 1995894]
    CCRF-CEM GI50
    0.0998 3
    Compound: Ara-C
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)
    		[PMID: 11597404]
    CCRF-CEM GI50
    0.09 3
    Compound: Ara-C
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)
    		[PMID: 11597404]
    CCRF-CEM IC50
    0.0037 3
    Compound: araC
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells
    		10.1016/S0960-894X(97)00044-9
    CCRF-CEM IC50
    0.065 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.
    		[PMID: 1992123]
    CCRF-CEM IC50
    0.001 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    		[PMID: 19674903]
    CCRF S-180 ED50
    0.2 3
    Compound: ara-C
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    CCRF S-180 ED50
    0.2 3
    Compound: ara-C
    Effective dose to inhibit the replication of S180 cell line in vitro.
    Effective dose to inhibit the replication of S180 cell line in vitro.
    		[PMID: 1995894]
    CCRF-CEM IC50
    0.006 3
    Compound: Ara-C
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    CCRF-CEM IC50
    0.024 3
    Compound: cytarabine
    Cytotoxicity against human CEM cells after 2 days
    Cytotoxicity against human CEM cells after 2 days
    		[PMID: 19910080]
    CCRF-CEM IC50
    0.024 3
    Compound: ara-C, cytarabine
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    		[PMID: 20000418]
    CCRF-CEM IC50
    0.09 3
    Compound: 6
    In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).
    In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).
    		[PMID: 8917645]
    CCRF S-180 IC50
    25.43 3
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    CCRF-CEM IC50
    0.32 6
    Compound: Ara-C
    In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.
    In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.
    		[PMID: 1995905]
    CCRF S-180 IC50
    40.33 3
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    CCRF-CEM IC50
    0.065 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.
    		[PMID: 3373480]
    CCRF-CEM/ara-C IC50
    0.1 2
    Compound: Ara-C
    Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines
    Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines
    		[PMID: 6827546]
    CCRF-HSB-2 IC50
    0.0086 6
    Compound: araC
    Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
    Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
    		[PMID: 9216836]
    CCRF-HSB-2 IC50
    0.047 6
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    		[PMID: 17644399]
    CCRF-HSB-2 IC50
    0.017 6
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    		[PMID: 18723355]
    CCRF-HSB-2 IC50
    0.047 6
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    		[PMID: 17962027]
    CCRF-HSB-2 IC50
    0.15 3
    Compound: ara-C
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    		[PMID: 17049252]
    CCRF-HSB-2 IC50
    0.017 6
    Compound: AraC
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    		[PMID: 18819815]
    CML/BC IC50
    0.21 3
    Compound: ara-C
    Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)
    Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)
    		[PMID: 3761322]
    COLO 320 IC50
    0.04 3
    Compound: ara-c
    Tested in vitro against colo-320 human colon adenocarcinoma
    Tested in vitro against colo-320 human colon adenocarcinoma
    		[PMID: 8277499]
    DLD-1 IC50
    >5 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against colon DLD-1 cells
    In vitro cytotoxicity was evaluated against colon DLD-1 cells
    		[PMID: 10780904]
    Glioblastoma cell line IC50
    >100 3
    Compound: ara-C
    Compound was tested for the inhibition of glioblastoma
    Compound was tested for the inhibition of glioblastoma
    		[PMID: 3761322]
    CCRF-CEM EC50
    0.00561 3
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CCRF-CEM EC50
    0.0228 3
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    H22 IC50
    25.98 3
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    H22 IC50
    37.82 3
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    CCRF-CEM ED50
    0.005 3
    Compound: ara-C
    Inhibit the replication of CCRF-CEM cell line in vitro.
    Inhibit the replication of CCRF-CEM cell line in vitro.
    		[PMID: 1995894]
    HCT-116 GI50
    0.12 3
    Compound: Ara-C
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    CCRF-CEM ED50
    0.006 3
    Compound: ara-C
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    HCT-116 IC50
    0.1 3
    Compound: Ara-C
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    CCRF-CEM ED50
    120 3
    Compound: ara-C
    Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)
    Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)
    		[PMID: 1652024]
    CCRF-CEM GI50
    0.09 3
    Compound: Ara-C
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)
    		[PMID: 11597404]
    HCT-116 IC50
    4.4 3
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    HCT-116 IC50
    2.42 3
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    CCRF-CEM GI50
    0.0998 3
    Compound: Ara-C
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)
    In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)
    		[PMID: 11597404]
    CCRF-CEM IC50
    0.001 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    		[PMID: 19674903]
    HCT-116 IC50
    5.3 3
    Compound: 2, Ara-C
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    		[PMID: 24956556]
    HCT-116 IC50
    5.3 3
    Compound: 1, ara-C
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    		[PMID: 19691349]
    CCRF-CEM IC50
    0.0037 3
    Compound: araC
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells
    		10.1016/S0960-894X(97)00044-9
    CCRF-CEM IC50
    0.006 3
    Compound: Ara-C
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    HeLa ED50
    0.05 6
    Compound: AraC
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    		[PMID: 178873]
    HeLa GI50
    0.18 3
    Compound: Ara-C
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    CCRF-CEM IC50
    0.024 3
    Compound: ara-C, cytarabine
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    		[PMID: 20000418]
    HeLa IC50
    0.95 3
    Compound: ARA
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 29886320]
    CCRF-CEM IC50
    0.024 3
    Compound: cytarabine
    Cytotoxicity against human CEM cells after 2 days
    Cytotoxicity against human CEM cells after 2 days
    		[PMID: 19910080]
    CCRF-CEM IC50
    0.065 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.
    		[PMID: 1992123]
    HeLa IC50
    464.433 3
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 19321234]
    CCRF-CEM IC50
    0.065 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.
    		[PMID: 3373480]
    HeLa IC50
    3.54 3
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 23867603]
    CCRF-CEM IC50
    0.09 3
    Compound: 6
    In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).
    In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).
    		[PMID: 8917645]
    HeLa IC50
    3.54 3
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    CCRF-CEM IC50
    0.32 6
    Compound: Ara-C
    In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.
    In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.
    		[PMID: 1995905]
    HeLa IC50
    0.26 3
    Compound: ara-C, cytarabine
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    		[PMID: 20000418]
    CCRF-CEM IC50
    6.0 x 10-7 41
    Compound: Ara-C
    Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines
    Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines
    		[PMID: 6827546]
    HeLa IC50
    3.54 3
    Compound: ara-C
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    CCRF-CEM/ara-C IC50
    0.0001 41
    Compound: Ara-C
    Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines
    Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines
    		[PMID: 6827546]
    HeLa IC50
    0.23 6
    Compound: cytosine arabinoside
    Cytotoxicity against human HeLa S3 cells
    Cytotoxicity against human HeLa S3 cells
    		[PMID: 10425135]
    CCRF-HSB-2 IC50
    0.0086 6
    Compound: araC
    Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
    Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
    		[PMID: 9216836]
    HeLa IC50
    3.54 3
    Compound: ara-C
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    CCRF-HSB-2 IC50
    0.017 6
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    		[PMID: 18723355]
    HeLa S3 ED50
    2.13 6
    Compound: cytosine arabinoside
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    CCRF-HSB-2 IC50
    0.017 6
    Compound: AraC
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    		[PMID: 18819815]
    HepG2 IC50
    26.23 3
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    HepG2 IC50
    38.1 3
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    CCRF-HSB-2 IC50
    0.047 6
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    		[PMID: 17644399]
    HepG2 IC50
    0.2 3
    Compound: Ara-C
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 20692841]
    CCRF-HSB-2 IC50
    0.047 6
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    		[PMID: 17962027]
    CCRF-HSB-2 IC50
    0.15 3
    Compound: ara-C
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    		[PMID: 17049252]
    HepG2 IC50
    2.86 3
    Compound: Cytarabine
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    HepG2 IC50
    2.86 3
    Compound: ara-C
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    HepG2 IC50
    2.86 3
    Compound: ara-C
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    CML/BC IC50
    0.21 3
    Compound: ara-C
    Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)
    Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)
    		[PMID: 3761322]
    HL-60 EC50
    0.6572 3
    Compound: cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    COLO 320 IC50
    0.04 3
    Compound: ara-c
    Tested in vitro against colo-320 human colon adenocarcinoma
    Tested in vitro against colo-320 human colon adenocarcinoma
    		[PMID: 8277499]
    HL-60 ED50
    30 3
    Compound: ara-C
    Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined
    Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined
    		[PMID: 3027329]
    HL-60 ED50
    0.047 3
    Compound: ara-C
    Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)
    Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)
    		[PMID: 3027329]
    DLD-1 IC50
    > 5 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against colon DLD-1 cells
    In vitro cytotoxicity was evaluated against colon DLD-1 cells
    		[PMID: 10780904]
    HL-60 IC50
    0.185 3
    Compound: Cytarabine
    Antiproliferative activity against human HL60 cells
    Antiproliferative activity against human HL60 cells
    		[PMID: 30114661]
    HL-60 IC50
    0.13 3
    Compound: ara-C
    Compound was tested for the inhibition of human HL60 Leukemia
    Compound was tested for the inhibition of human HL60 Leukemia
    		[PMID: 3761322]
    HL-60 IC50
    >0.1 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.
    		[PMID: 1992123]
    HL-60 IC50
    0.118 3
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 19321234]
    Glioblastoma cell line IC50
    > 100 3
    Compound: ara-C
    Compound was tested for the inhibition of glioblastoma
    Compound was tested for the inhibition of glioblastoma
    		[PMID: 3761322]
    HL-60 IC50
    0.049 3
    Compound: Ara-C
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    HL-60 IC50
    0.35 3
    Compound: citarabine
    In vitro concentration required to induce apoptosis in HL60R cells
    In vitro concentration required to induce apoptosis in HL60R cells
    		[PMID: 12877593]
    H22 IC50
    25.98 3
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    H22 IC50
    37.82 3
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    HL-60 IC50
    >0.1 6
    Compound: Ara-C
    In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.
    In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.
    		[PMID: 1995905]
    HL-60 IC50
    0.08 3
    Compound: citarabine
    In vitro inhibitory concentration against proliferation of HL60 cells
    In vitro inhibitory concentration against proliferation of HL60 cells
    		[PMID: 12877593]
    HCT-116 GI50
    0.12 3
    Compound: Ara-C
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    HL-60 IC50
    0.76 3
    Compound: ara-C
    Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
    Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
    		[PMID: 12954073]
    HCT-116 IC50
    0.1 3
    Compound: Ara-C
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    HCT-116 IC50
    2.42 3
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    HL-60 IC50
    0.029 6
    Compound: ara-C
    The cytotoxic activity in HL-60 cells
    The cytotoxic activity in HL-60 cells
    		[PMID: 9371251]
    HCT-116 IC50
    4.4 3
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    HL60/MX2 EC50
    0.2612 3
    Compound: cytarabine
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    HOS-TE85 IC50
    2.6 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells
    In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells
    		[PMID: 2002478]
    HCT-116 IC50
    5.3 3
    Compound: 1, ara-C
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    		[PMID: 19691349]
    HCT-116 IC50
    5.3 3
    Compound: 2, Ara-C
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    		[PMID: 24956556]
    HOS-TE85 IC50
    10.7 3
    Compound: ara-c
    Tested in vitro against MNNG/HOS cell line human osteosarcoma
    Tested in vitro against MNNG/HOS cell line human osteosarcoma
    		[PMID: 8277499]
    HT-1080 IC50
    0.13 6
    Compound: 2
    In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells
    In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells
    		[PMID: 2002478]
    HCT-116 IC50
    5.3 3
    Compound: AraC
    Cytotoxicity against human HCT-116 cells
    Cytotoxicity against human HCT-116 cells
    		[PMID: 38716896]
    HT-1080 IC50
    0.53 3
    Compound: ara-c
    Tested in vitro against HT1080 cell line human fibrosarcoma
    Tested in vitro against HT1080 cell line human fibrosarcoma
    		[PMID: 8277499]
    HUVEC GI50
    0.23 3
    Compound: Ara-C
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    		[PMID: 22264170]
    HL-60 EC50
    0.6572 3
    Compound: cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    Jurkat E6.1 IC50
    0.018 3
    Compound: Cytarabine
    Antiproliferative activity against human Jurkat E6-1 cells
    Antiproliferative activity against human Jurkat E6-1 cells
    		[PMID: 30114661]
    HL-60 ED50
    0.047 3
    Compound: ara-C
    Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)
    Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)
    		[PMID: 3027329]
    K562 IC50
    500 2
    Compound: ara-C
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 18571290]
    HL-60 ED50
    30 3
    Compound: ara-C
    Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined
    Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined
    		[PMID: 3027329]
    K562 IC50
    24.29 3
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    K562 IC50
    43.61 3
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    HL-60 IC50
    0.029 6
    Compound: ara-C
    The cytotoxic activity in HL-60 cells
    The cytotoxic activity in HL-60 cells
    		[PMID: 9371251]
    K562 IC50
    3.2 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.
    		[PMID: 1992123]
    HL-60 IC50
    0.049 3
    Compound: Ara-C
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    HL-60 IC50
    0.08 3
    Compound: citarabine
    In vitro inhibitory concentration against proliferation of HL60 cells
    In vitro inhibitory concentration against proliferation of HL60 cells
    		[PMID: 12877593]
    K562 IC50
    33.5 3
    Compound: Ara-C
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    		[PMID: 20692841]
    HL-60 IC50
    0.118 3
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 19321234]
    K562 IC50
    14 3
    Compound: Ara-C
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    HL-60 IC50
    0.13 3
    Compound: ara-C
    Compound was tested for the inhibition of human HL60 Leukemia
    Compound was tested for the inhibition of human HL60 Leukemia
    		[PMID: 3761322]
    K562 IC50
    0.05 3
    Compound: 2, Ara-C
    Cytotoxicity against human K562 cells by SRB assay
    Cytotoxicity against human K562 cells by SRB assay
    		[PMID: 24956556]
    HL-60 IC50
    0.185 3
    Compound: Cytarabine
    Antiproliferative activity against human HL60 cells
    Antiproliferative activity against human HL60 cells
    		[PMID: 30114661]
    K562 IC50
    0.05 3
    Compound: 1, ara-C
    Cytotoxicity against human K562 cells by sulforhodamine B method
    Cytotoxicity against human K562 cells by sulforhodamine B method
    		[PMID: 19691349]
    K562 IC50
    3.2 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.
    In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.
    		[PMID: 3373480]
    HL-60 IC50
    0.35 3
    Compound: citarabine
    In vitro concentration required to induce apoptosis in HL60R cells
    In vitro concentration required to induce apoptosis in HL60R cells
    		[PMID: 12877593]
    HL-60 IC50
    0.76 3
    Compound: ara-C
    Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
    Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
    		[PMID: 12954073]
    KATO III stomach cancer cell line IC50
    >100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma KATO III solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma KATO III solid cell lines.
    		[PMID: 1992123]
    HL-60 IC50
    > 0.1 6
    Compound: Ara-C
    In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.
    In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.
    		[PMID: 1995905]
    KATO III stomach cancer cell line IC50
    >100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human gastric carcinoma (KATO III) cell line.
    In vitro inhibitory activity against Human gastric carcinoma (KATO III) cell line.
    		[PMID: 1995905]
    KATO III stomach cancer cell line IC50
    0.3 3
    Compound: ara-C
    Tested for in vitro cytotoxicity against KATO III human stomach adenocarcinoma cell line
    Tested for in vitro cytotoxicity against KATO III human stomach adenocarcinoma cell line
    		[PMID: 8277500]
    HL-60 IC50
    > 0.1 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.
    		[PMID: 1992123]
    KATO III stomach cancer cell line IC50
    >410 3
    Compound: ara-c
    Tested in vitro against KATO-III human stomach adenocarcinoma
    Tested in vitro against KATO-III human stomach adenocarcinoma
    		[PMID: 8277499]
    KB ED50
    2.84 6
    Compound: cytosine arabinoside
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    KB ED50
    0.99 6
    Compound: Cytosine arabinoside
    Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis
    Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis
    		[PMID: 21194944]
    KB IC50
    0.23 6
    Compound: Ara-C
    Antitumor activity against human KB cells by modified MTT assay
    Antitumor activity against human KB cells by modified MTT assay
    		[PMID: 17644399]
    KB IC50
    0.23 6
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    		[PMID: 17962027]
    HL60/MX2 EC50
    0.2612 3
    Compound: cytarabine
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    KB IC50
    0.73 6
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    		[PMID: 18723355]
    KB IC50
    0.81 6
    Compound: cytosine arabinoside
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 10425135]
    KB IC50
    4.07 3
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 23867603]
    HOS-TE85 IC50
    10.7 3
    Compound: ara-c
    Tested in vitro against MNNG/HOS cell line human osteosarcoma
    Tested in vitro against MNNG/HOS cell line human osteosarcoma
    		[PMID: 8277499]
    KB IC50
    4.07 3
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    HOS-TE85 IC50
    2.6 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells
    In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells
    		[PMID: 2002478]
    HT-1080 IC50
    0.13 6
    Compound: 2
    In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells
    In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells
    		[PMID: 2002478]
    KB IC50
    0.99 6
    Compound: Cytarabine
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    		[PMID: 21945463]
    KB IC50
    4.07 3
    Compound: ara-C
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    HT-1080 IC50
    0.53 3
    Compound: ara-c
    Tested in vitro against HT1080 cell line human fibrosarcoma
    Tested in vitro against HT1080 cell line human fibrosarcoma
    		[PMID: 8277499]
    KB IC50
    4.07 3
    Compound: ara-C
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    HT-29 IC50
    66 1
    Compound: cytosine arabinoside
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    		[PMID: 2778449]
    HUVEC GI50
    0.23 3
    Compound: Ara-C
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    		[PMID: 22264170]
    KB IC50
    0.14 6
    Compound: Ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    		[PMID: 18055068]
    HeLa ED50
    0.05 6
    Compound: AraC
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    		[PMID: 178873]
    KB IC50
    0.7 3
    Compound: ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    		[PMID: 17049252]
    HeLa GI50
    0.18 3
    Compound: Ara-C
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    KB IC50
    0.42 6
    Compound: AraC
    Growth inhibition of human KB cells by MTT method
    Growth inhibition of human KB cells by MTT method
    		[PMID: 18819815]
    HeLa IC50
    0.23 6
    Compound: cytosine arabinoside
    Cytotoxicity against human HeLa S3 cells
    Cytotoxicity against human HeLa S3 cells
    		[PMID: 10425135]
    KB IC50
    30.5 6
    Compound: Ara-C
    In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.
    In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.
    		[PMID: 1995905]
    HeLa IC50
    0.26 3
    Compound: ara-C, cytarabine
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    		[PMID: 20000418]
    KB IC50
    0.64 3
    Compound: ara-C
    Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line
    Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line
    		[PMID: 8277500]
    HeLa IC50
    0.95 3
    Compound: ARA
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 29886320]
    KB IC50
    2.3 3
    Compound: ara-c
    Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells
    Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells
    		[PMID: 8277499]
    HeLa IC50
    3.54 3
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 23867603]
    KHOS-321H IC50
    0.27 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells
    In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells
    		[PMID: 2002478]
    KKLS IC50
    >410 3
    Compound: ara-c
    Tested in vitro against KKLS human stomach adenocarcinoma
    Tested in vitro against KKLS human stomach adenocarcinoma
    		[PMID: 8277499]
    HeLa IC50
    3.54 3
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    HeLa IC50
    3.54 3
    Compound: ara-C
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    L02 IC50
    0.21 3
    Compound: ARA
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    		[PMID: 30852384]
    HeLa IC50
    3.54 3
    Compound: ara-C
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    L02 IC50
    0.17 3
    Compound: ARA
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 29886320]
    HeLa IC50
    464.433 3
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 19321234]
    L1210 ED50
    0.05 3
    Compound: ara-C
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    L1210 ED50
    2.76 6
    Compound: cytosine arabinoside
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    L1210 ED50
    0.1 3
    Compound: ara-C
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    		[PMID: 118258]
    HeLa S3 ED50
    2.13 6
    Compound: cytosine arabinoside
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    L1210 ED50
    0.05 3
    Compound: ara-C
    Effective dose to inhibit the replication of L1210 cell line in vitro.
    Effective dose to inhibit the replication of L1210 cell line in vitro.
    		[PMID: 1995894]
    L1210 ED50
    0.1 3
    Compound: ara-C
    In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line
    In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line
    		[PMID: 7143370]
    HepG2 IC50
    0.2 3
    Compound: Ara-C
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 20692841]
    HepG2 IC50
    2.86 3
    Compound: Cytarabine
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    L1210 ED50
    0.19 3
    Compound: ara-C
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    		[PMID: 3968680]
    HepG2 IC50
    2.86 3
    Compound: ara-C
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    L1210 ED50
    0.03 3
    Compound: ara-C
    Inhibition of thymidylate synthase in L1210 cells
    Inhibition of thymidylate synthase in L1210 cells
    		[PMID: 3027329]
    L1210 IC50
    0.17 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against murine leukemia L1210
    Anticancer activity carried out in vitro against murine leukemia L1210
    		[PMID: 11356110]
    HepG2 IC50
    2.86 3
    Compound: ara-C
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    HepG2 IC50
    26.23 3
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    L1210 IC50
    0.097 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.
    Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.
    		[PMID: 1992123]
    L1210 IC50
    103 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    		[PMID: 19674903]
    HepG2 IC50
    38.1 3
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    L1210 IC50
    0.024 3
    Compound: cytarabine
    Cytotoxicity against mouse L1210 cells after 2 days
    Cytotoxicity against mouse L1210 cells after 2 days
    		[PMID: 19910080]
    Jurkat E6.1 IC50
    0.018 3
    Compound: Cytarabine
    Antiproliferative activity against human Jurkat E6-1 cells
    Antiproliferative activity against human Jurkat E6-1 cells
    		[PMID: 30114661]
    L1210 IC50
    0.024 3
    Compound: ara-C, cytarabine
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    		[PMID: 20000418]
    L1210 IC50
    0.097 6
    Compound: ara-C
    In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.
    In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.
    		[PMID: 3373480]
    L1210 IC50
    0.1 3
    Compound: 1
    Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)
    Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)
    		[PMID: 1527783]
    L1210 IC50
    0.01 3
    Compound: 1
    Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)
    Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)
    		[PMID: 1527783]
    L1210 IC50
    0.08 3
    Compound: araC
    Inhibitory activity against murine leukemia L1210 cells
    Inhibitory activity against murine leukemia L1210 cells
    		[PMID: 1992143]
    L1210 IC50
    0.036 3
    Compound: ara-C
    Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
    Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
    		[PMID: 1906107]
    L1210 IC50
    0.031 3
    Compound: araC
    Tested for its antiproliferative activity on murine leukemia L1210 cells
    Tested for its antiproliferative activity on murine leukemia L1210 cells
    		10.1016/S0960-894X(97)00044-9
    L1210 IC50
    0.12 3
    Compound: ara-C
    Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse
    Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse
    		[PMID: 8277500]
    L1210 IC50
    0.05 3
    Compound: ara-c
    Tested in vitro inhibitory activity against murine leukemia L1210
    Tested in vitro inhibitory activity against murine leukemia L1210
    		[PMID: 8277499]
    Lewis lung carcinoma cell line IC50
    5.6 3
    Compound: ara-C
    Tested for in vitro cytotoxicity against LLC Lewis lung carcinoma cell line
    Tested for in vitro cytotoxicity against LLC Lewis lung carcinoma cell line
    		[PMID: 8277500]
    MCF7 IC50
    1.03 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against breast carcinoma MCF-7
    Anticancer activity carried out in vitro against breast carcinoma MCF-7
    		[PMID: 11356110]
    MCF7 IC50
    >= 100 3
    Compound: Ara-C
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    K562 IC50
    0.05 3
    Compound: 1, ara-C
    Cytotoxicity against human K562 cells by sulforhodamine B method
    Cytotoxicity against human K562 cells by sulforhodamine B method
    		[PMID: 19691349]
    MCF7 IC50
    0.04 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    		[PMID: 19674903]
    K562 IC50
    0.05 3
    Compound: 2, Ara-C
    Cytotoxicity against human K562 cells by SRB assay
    Cytotoxicity against human K562 cells by SRB assay
    		[PMID: 24956556]
    MCF7 IC50
    0.004 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    		[PMID: 19674903]
    K562 IC50
    0.05 3
    Compound: AraC
    Cytotoxicity against human K562 cells
    Cytotoxicity against human K562 cells
    		[PMID: 38716896]
    MCF7 IC50
    3.82 3
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 23867603]
    K562 IC50
    14 3
    Compound: Ara-C
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    K562 IC50
    24.29 3
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    MCF7 IC50
    >20 3
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    		[PMID: 35665692]
    K562 IC50
    3.2 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.
    		[PMID: 1992123]
    MCF7 IC50
    0.93 6
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    		[PMID: 21945463]
    MCF7 IC50
    3.82 3
    Compound: ara-C
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    K562 IC50
    3.2 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.
    In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.
    		[PMID: 3373480]
    K562 IC50
    33.5 3
    Compound: Ara-C
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    		[PMID: 20692841]
    MCF7 IC50
    3.82 3
    Compound: Cytarabine
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    K562 IC50
    43.61 3
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		10.1039/C0MD00208A
    HT-29 IC50
    66 1
    Compound: cytosine arabinoside
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    		[PMID: 2778449]
    K562 IC50
    500 2
    Compound: ara-C
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 18571290]
    MCF7 IC50
    0.62 3
    Compound: ara-c
    Tested in vitro against MCF-7 human breast adenocarcinoma
    Tested in vitro against MCF-7 human breast adenocarcinoma
    		[PMID: 8277499]
    MDA-MB-231 IC50
    10.49 3
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    K562 IC50
    500 1
    Compound: ara-c
    Inhibition of cell growth against human myeloid leukemia K562(S) cells
    Inhibition of cell growth against human myeloid leukemia K562(S) cells
    		[PMID: 10560743]
    MDA-MB-231 IC50
    1.37 3
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    KB ED50
    0.99 6
    Compound: Cytosine arabinoside
    Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis
    Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis
    		[PMID: 21194944]
    MES-SA IC50
    1.7 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    		[PMID: 19674903]
    KB ED50
    2.84 6
    Compound: cytosine arabinoside
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    KB IC50
    0.14 6
    Compound: Ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    		[PMID: 18055068]
    MKN-28 IC50
    4.5 6
    Compound: 2
    In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells
    In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells
    		[PMID: 2002478]
    KB IC50
    0.23 6
    Compound: Ara-C
    Antitumor activity against human KB cells by modified MTT assay
    Antitumor activity against human KB cells by modified MTT assay
    		[PMID: 17644399]
    MKN-45 IC50
    57.6 3
    Compound: ara-c
    Tested in vitro against MKN-45 human stomach adenocarcinoma
    Tested in vitro against MKN-45 human stomach adenocarcinoma
    		[PMID: 8277499]
    MOLT-3 ED50
    2.67 6
    Compound: cytosine arabinoside
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    KB IC50
    0.23 6
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    		[PMID: 17962027]
    KB IC50
    0.42 6
    Compound: AraC
    Growth inhibition of human KB cells by MTT method
    Growth inhibition of human KB cells by MTT method
    		[PMID: 18819815]
    MOLT-4 IC50
    0.65 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8
    Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8
    		[PMID: 11356110]
    MOLT-4 IC50
    1 3
    Compound: Ara-C
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    KB IC50
    0.64 3
    Compound: ara-C
    Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line
    Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line
    		[PMID: 8277500]
    KB IC50
    0.7 3
    Compound: ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    		[PMID: 17049252]
    MOLT-4 IC50
    0.03 3
    Compound: araC
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells
    		10.1016/S0960-894X(97)00044-9
    KB IC50
    0.73 6
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    		[PMID: 18723355]
    MOLT-4 IC50
    0.056 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.
    		[PMID: 1992123]
    KB IC50
    0.81 6
    Compound: cytosine arabinoside
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 10425135]
    MOLT-4 IC50
    0.056 6
    Compound: Ara-C
    In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.
    In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.
    		[PMID: 1995905]
    KB IC50
    0.99 6
    Compound: Cytarabine
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    		[PMID: 21945463]
    MOLT-4 IC50
    0.056 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.
    		[PMID: 3373480]
    MPC-11 ED50
    0.99 3
    Compound: ara-C
    In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line
    In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line
    		[PMID: 7143370]
    KB IC50
    2.3 3
    Compound: ara-c
    Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells
    Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells
    		[PMID: 8277499]
    MV4-11 IC50
    3.36 3
    Compound: AraC
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    		[PMID: 20153646]
    KB IC50
    30.5 6
    Compound: Ara-C
    In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.
    In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.
    		[PMID: 1995905]
    KB IC50
    4.07 3
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 23867603]
    NCC IC50
    0.13 6
    Compound: 2
    In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells
    In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells
    		[PMID: 2002478]
    KB IC50
    4.07 3
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    NCI-H23 IC50
    1 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1
    In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1
    		[PMID: 10780904]
    KB IC50
    4.07 3
    Compound: ara-C
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    NCI-H460 IC50
    0.1 3
    Compound: Ara-C
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    NHDF IC50
    4.99 3
    Compound: ara-C
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    KB IC50
    4.07 3
    Compound: ara-C
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    NHDF IC50
    4.99 3
    Compound: ara-C
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    Non-small cell lung cancer cell line IC50
    34 3
    Compound: ara-C
    Compound was tested for the inhibition of non- small cell lung cancer
    Compound was tested for the inhibition of non- small cell lung cancer
    		[PMID: 3761322]
    KHOS-321H IC50
    0.27 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells
    In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells
    		[PMID: 2002478]
    NUGC-3 GI50
    0.25 3
    Compound: Ara-C
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    KKLS IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against KKLS human stomach adenocarcinoma
    Tested in vitro against KKLS human stomach adenocarcinoma
    		[PMID: 8277499]
    OST IC50
    >410 3
    Compound: ara-c
    Tested in vitro against OST human osteosarcoma
    Tested in vitro against OST human osteosarcoma
    		[PMID: 8277499]
    P388 ED50
    0.02 3
    Compound: ara-C
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    P388 ED50
    0.02 3
    Compound: ara-C
    Effective dose to inhibit the replication of P388 cell line in vitro.
    Effective dose to inhibit the replication of P388 cell line in vitro.
    		[PMID: 1995894]
    P388 IC50
    0.14 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against murine leukemia P388
    Anticancer activity carried out in vitro against murine leukemia P388
    		[PMID: 11356110]
    PBMC IC50
    181 3
    Compound: Cytarabin
    Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay
    Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay
    		[PMID: 38064359]
    PC10 IC50
    >100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.
    		[PMID: 1992123]
    PC10 IC50
    >100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.
    In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.
    		[PMID: 1995905]
    L02 IC50
    0.17 3
    Compound: ARA
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 29886320]
    PC10 IC50
    >100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).
    In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).
    		[PMID: 3373480]
    L02 IC50
    0.21 3
    Compound: ARA
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    		[PMID: 30852384]
    PC-13 IC50
    >100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.
    In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.
    		[PMID: 1995905]
    PC-13 IC50
    >410 3
    Compound: ara-c
    Tested in vitro against PC-13 human lung large cell carcinoma
    Tested in vitro against PC-13 human lung large cell carcinoma
    		[PMID: 8277499]
    PC-14 IC50
    >100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.
    		[PMID: 1992123]
    PC-14 IC50
    >100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.
    In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.
    		[PMID: 1995905]
    K562 IC50
    500 1
    Compound: ara-c
    Inhibition of cell growth against human myeloid leukemia K562(S) cells
    Inhibition of cell growth against human myeloid leukemia K562(S) cells
    		[PMID: 10560743]
    PC-3 IC50
    0.81 3
    Compound: ara-C
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    PC-3 IC50
    48.4 3
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    PC-3 IC50
    50.51 3
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    PC-3 IC50
    55.9 3
    Compound: 2, Ara-C
    Cytotoxicity against human PC3 cells by SRB assay
    Cytotoxicity against human PC3 cells by SRB assay
    		[PMID: 24956556]
    PC-3 IC50
    55.9 3
    Compound: 1, ara-C
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    		[PMID: 19691349]
    L1210 ED50
    0.03 3
    Compound: ara-C
    Inhibition of thymidylate synthase in L1210 cells
    Inhibition of thymidylate synthase in L1210 cells
    		[PMID: 3027329]
    PC-6 IC50
    50 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.
    In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.
    		[PMID: 1995905]
    L1210 ED50
    0.05 3
    Compound: ara-C
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    PC-6 IC50
    50 6
    Compound: 2
    In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells
    In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells
    		[PMID: 2002478]
    L1210 ED50
    0.05 3
    Compound: ara-C
    Effective dose to inhibit the replication of L1210 cell line in vitro.
    Effective dose to inhibit the replication of L1210 cell line in vitro.
    		[PMID: 1995894]
    L1210 ED50
    0.1 3
    Compound: ara-C
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    		[PMID: 118258]
    PC-8 IC50
    0.28 6
    Compound: 2
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells
    		[PMID: 2002478]
    L1210 ED50
    0.1 3
    Compound: ara-C
    In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line
    In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line
    		[PMID: 7143370]
    PC-8 IC50
    1.1 3
    Compound: ara-c
    Tested in vitro against PC-8 human lung adenocarcinoma
    Tested in vitro against PC-8 human lung adenocarcinoma
    		[PMID: 8277499]
    L1210 ED50
    0.19 3
    Compound: ara-C
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    		[PMID: 3968680]
    PC-9 IC50
    1.6 6
    Compound: 2
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells
    		[PMID: 2002478]
    PC-9 IC50
    6.6 3
    Compound: ara-c
    Tested in vitro against PC-9 human lung adenocarcinoma
    Tested in vitro against PC-9 human lung adenocarcinoma
    		[PMID: 8277499]
    L1210 ED50
    2.76 6
    Compound: cytosine arabinoside
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    QG-95 IC50
    >410 3
    Compound: ara-c
    Tested in vitro against QG-95 human squamous cell carcinoma
    Tested in vitro against QG-95 human squamous cell carcinoma
    		[PMID: 8277499]
    L1210 IC50
    0.0004 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    		[PMID: 19674903]
    L1210 IC50
    0.01 3
    Compound: 1
    Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)
    Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)
    		[PMID: 1527783]
    RS4-11 IC50
    0.26 3
    Compound: AraC
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    		[PMID: 20153646]
    SAOS-2 IC50
    2.7 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells
    In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells
    		[PMID: 2002478]
    L1210 IC50
    0.01 3
    Compound: 1
    Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr)
    Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr)
    		[PMID: 1527783]
    SF-268 IC50
    7.68 3
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    		[PMID: 20356655]
    L1210 IC50
    0.024 3
    Compound: ara-C, cytarabine
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    		[PMID: 20000418]
    SF-268 IC50
    7.68 × 10-3 3
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells by MTT assay
    Cytotoxicity against human SF268 cells by MTT assay
    		[PMID: 19345581]
    L1210 IC50
    0.024 3
    Compound: cytarabine
    Cytotoxicity against mouse L1210 cells after 2 days
    Cytotoxicity against mouse L1210 cells after 2 days
    		[PMID: 19910080]
    P388 IC50
    1233 1
    Compound: cytosine arabinoside
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    		[PMID: 2778449]
    L1210 IC50
    0.031 3
    Compound: araC
    Tested for its antiproliferative activity on murine leukemia L1210 cells
    Tested for its antiproliferative activity on murine leukemia L1210 cells
    		10.1016/S0960-894X(97)00044-9
    L1210 IC50
    0.036 3
    Compound: ara-C
    Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
    Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
    		[PMID: 1906107]
    SK-BR-3 IC50
    0.87 3
    Compound: ara-C
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    L1210 IC50
    0.036 3
    Compound: ara-C
    Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
    Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
    		[PMID: 1906107]
    SK-ES1 IC50
    0.09 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells
    In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells
    		[PMID: 2002478]
    SK-HEP1 IC50
    1.8 3
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    L1210 IC50
    0.05 3
    Compound: ara-c
    Tested in vitro inhibitory activity against murine leukemia L1210
    Tested in vitro inhibitory activity against murine leukemia L1210
    		[PMID: 8277499]
    SK-HEP1 IC50
    2.12 3
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    L1210 IC50
    0.08 3
    Compound: araC
    Inhibitory activity against murine leukemia L1210 cells
    Inhibitory activity against murine leukemia L1210 cells
    		[PMID: 1992143]
    L1210 IC50
    0.097 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.
    Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.
    		[PMID: 1992123]
    SK-MEL-28 IC50
    1 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells
    In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells
    		[PMID: 10780904]
    SK-MEL-28 IC50
    11.1 6
    Compound: Ara-C
    In vitro inhibitory activity against Human melanoma (P-36) cell line.
    In vitro inhibitory activity against Human melanoma (P-36) cell line.
    		[PMID: 1995905]
    L1210 IC50
    0.097 6
    Compound: ara-C
    In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.
    In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.
    		[PMID: 3373480]
    L1210 IC50
    0.1 3
    Compound: 1
    Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)
    Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)
    		[PMID: 1527783]
    SK-OV-3 IC50
    0.99 3
    Compound: ara-C
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    L1210 IC50
    0.12 3
    Compound: ara-C
    Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse
    Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse
    		[PMID: 8277500]
    Small cell lung cancer cell line IC50
    >100 3
    Compound: ara-C
    Compound was tested for the inhibition of small cell lung cancer
    Compound was tested for the inhibition of small cell lung cancer
    		[PMID: 3761322]
    L1210 IC50
    0.17 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against murine leukemia L1210
    Anticancer activity carried out in vitro against murine leukemia L1210
    		[PMID: 11356110]
    SMMC-7721 IC50
    0.013 3
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 29886320]
    L1210 IC50
    103 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    		[PMID: 19674903]
    SMMC-7721 IC50
    0.0271 3
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    		[PMID: 30852384]
    SNB-7 IC50
    1 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1
    In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1
    		[PMID: 10780904]
    SNU-638 IC50
    1.08 3
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    SNU-638 IC50
    3.98 3
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    SNU-638 IC50
    0.15 3
    Compound: 2, Ara-C
    Cytotoxicity against human SNU638 cells by SRB assay
    Cytotoxicity against human SNU638 cells by SRB assay
    		[PMID: 24956556]
    SNU-638 IC50
    0.15 3
    Compound: 1, ara-C
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    		[PMID: 19691349]
    ST-KM-1 IC50
    >410 3
    Compound: ara-c
    Tested in vitro against ST-KM human stomach adenocarcinoma
    Tested in vitro against ST-KM human stomach adenocarcinoma
    		[PMID: 8277499]
    SW1573 IC50
    10500 3
    Compound: cytarabine
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    		[PMID: 17419604]
    SW48 IC50
    >410 3
    Compound: ara-c
    Tested in vitro against SW-48 human colon adenocarcinoma
    Tested in vitro against SW-48 human colon adenocarcinoma
    		[PMID: 8277499]
    SW480 ED50
    3.42 6
    Compound: cytosine arabinoside
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    SW480 IC50
    >100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.
    		[PMID: 1992123]
    SW480 IC50
    >100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.
    In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.
    		[PMID: 1995905]
    SW480 IC50
    >100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).
    In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).
    		[PMID: 3373480]
    SW-620 IC50
    30 3
    Compound: Ara-C
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    T-24 IC50
    >100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.
    		[PMID: 1992123]
    T-24 IC50
    0.5 6
    Compound: Ara-C
    In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.
    In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.
    		[PMID: 1995905]
    T-24 IC50
    0.5 6
    Compound: 2
    In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells
    In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells
    		[PMID: 2002478]
    T-24 IC50
    >100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).
    In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).
    		[PMID: 3373480]
    T47D IC50
    2.72 3
    Compound: 2, Ara-C
    Cytotoxicity against human T47D cells by SRB assay
    Cytotoxicity against human T47D cells by SRB assay
    		[PMID: 24956556]
    T47D IC50
    2.7 3
    Compound: 1, ara-C
    Cytotoxicity against human T47D cells by sulforhodamine B method
    Cytotoxicity against human T47D cells by sulforhodamine B method
    		[PMID: 19691349]
    TE-2 IC50
    >100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.
    		[PMID: 1992123]
    TE-2 IC50
    >100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.
    In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.
    		[PMID: 1995905]
    TE-2 IC50
    >100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).
    In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).
    		[PMID: 3373480]
    U-87MG ATCC CC50
    0.19 3
    Compound: 16
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    		[PMID: 35123007]
    U-87MG ATCC IC50
    0.85 3
    Compound: ara-C
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    U-87MG ATCC IC50
    2.88 3
    Compound: ara-C
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    U-937 IC50
    0.31 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.
    		[PMID: 1992123]
    U-937 IC50
    0.002 3
    Compound: Cytarabine
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    		[PMID: 30954427]
    U-937 IC50
    0.46 6
    Compound: Ara-C
    In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.
    In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.
    		[PMID: 1995905]
    Vero CC50
    4.8 6
    Compound: Ara-C
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    		[PMID: 12444692]
    Vero EC50
    1.6 6
    Compound: Ara-C
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		[PMID: 12444692]
    Vero EC50
    3 6
    Compound: Ara-C
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		[PMID: 12444692]
    WI-38 IC50
    >100 6
    Compound: CAR
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    		[PMID: 35963130]
    WI-38 IC50
    493.17 3
    Compound: CAR
    Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay
    		[PMID: 38516604]
    MCF7 IC50
    0.004 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    		[PMID: 19674903]
    MCF7 IC50
    0.04 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    		[PMID: 19674903]
    MCF7 IC50
    0.62 3
    Compound: ara-c
    Tested in vitro against MCF-7 human breast adenocarcinoma
    Tested in vitro against MCF-7 human breast adenocarcinoma
    		[PMID: 8277499]
    MCF7 IC50
    0.93 6
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    		[PMID: 21945463]
    MCF7 IC50
    1.03 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against breast carcinoma MCF-7
    Anticancer activity carried out in vitro against breast carcinoma MCF-7
    		[PMID: 11356110]
    MCF7 IC50
    3.82 3
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 23867603]
    MCF7 IC50
    3.82 3
    Compound: Cytarabine
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    		[PMID: 27073055]
    MCF7 IC50
    3.82 3
    Compound: ara-C
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    MCF7 IC50
    > 20 3
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    		[PMID: 35665692]
    MCF7 IC50
    >= 100 3
    Compound: Ara-C
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    MDA-MB-231 IC50
    1.37 3
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    MDA-MB-231 IC50
    10.49 3
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    MES-SA IC50
    1.7 3
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    		[PMID: 19674903]
    MKN-28 IC50
    4.5 6
    Compound: 2
    In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells
    In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells
    		[PMID: 2002478]
    MKN-45 IC50
    57.6 3
    Compound: ara-c
    Tested in vitro against MKN-45 human stomach adenocarcinoma
    Tested in vitro against MKN-45 human stomach adenocarcinoma
    		[PMID: 8277499]
    MOLT-3 ED50
    2.67 6
    Compound: cytosine arabinoside
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    MOLT-4 IC50
    0.03 3
    Compound: araC
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells
    Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells
    		10.1016/S0960-894X(97)00044-9
    MOLT-4 IC50
    0.056 6
    Compound: Ara-C
    In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.
    In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.
    		[PMID: 1995905]
    MOLT-4 IC50
    0.056 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.
    		[PMID: 1992123]
    MOLT-4 IC50
    0.056 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.
    In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.
    		[PMID: 3373480]
    MOLT-4 IC50
    0.65 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8
    Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8
    		[PMID: 11356110]
    MOLT-4 IC50
    1 3
    Compound: Ara-C
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    MOLT-4 IC50
    4.0 x 10-7 41
    Compound: Ara-C
    Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines
    Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines
    		[PMID: 6827546]
    MPC-11 ED50
    0.99 3
    Compound: ara-C
    In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line
    In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line
    		[PMID: 7143370]
    MV4-11 IC50
    3.36 3
    Compound: AraC
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    		[PMID: 20153646]
    NCC IC50
    0.13 6
    Compound: 2
    In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells
    In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells
    		[PMID: 2002478]
    NCI-H23 IC50
    1 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1
    In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1
    		[PMID: 10780904]
    NCI-H460 IC50
    0.1 3
    Compound: Ara-C
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    NHDF IC50
    4.99 3
    Compound: ara-C
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    NHDF IC50
    4.99 3
    Compound: ara-C
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    NUGC-3 GI50
    0.25 3
    Compound: Ara-C
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    		[PMID: 22264170]
    Non-small cell lung cancer cell line IC50
    34 3
    Compound: ara-C
    Compound was tested for the inhibition of non- small cell lung cancer
    Compound was tested for the inhibition of non- small cell lung cancer
    		[PMID: 3761322]
    OST IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against OST human osteosarcoma
    Tested in vitro against OST human osteosarcoma
    		[PMID: 8277499]
    P388 ED50
    0.02 3
    Compound: ara-C
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    		[PMID: 1652024]
    P388 ED50
    0.02 3
    Compound: ara-C
    Effective dose to inhibit the replication of P388 cell line in vitro.
    Effective dose to inhibit the replication of P388 cell line in vitro.
    		[PMID: 1995894]
    P388 IC50
    0.14 3
    Compound: Ara-C
    Anticancer activity carried out in vitro against murine leukemia P388
    Anticancer activity carried out in vitro against murine leukemia P388
    		[PMID: 11356110]
    P388 IC50
    1233 1
    Compound: cytosine arabinoside
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    		[PMID: 2778449]
    PBMC IC50
    181 3
    Compound: Cytarabin
    Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay
    Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay
    		[PMID: 38064359]
    PC-13 IC50
    > 100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.
    In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.
    		[PMID: 1995905]
    PC-13 IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against PC-13 human lung large cell carcinoma
    Tested in vitro against PC-13 human lung large cell carcinoma
    		[PMID: 8277499]
    PC-14 IC50
    > 100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.
    In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.
    		[PMID: 1995905]
    PC-14 IC50
    > 100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.
    		[PMID: 1992123]
    PC-3 IC50
    0.81 3
    Compound: ara-C
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    PC-3 IC50
    48.4 3
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    PC-3 IC50
    50.51 3
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    PC-3 IC50
    55.9 3
    Compound: 1, ara-C
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    		[PMID: 19691349]
    PC-3 IC50
    55.9 3
    Compound: 2, Ara-C
    Cytotoxicity against human PC3 cells by SRB assay
    Cytotoxicity against human PC3 cells by SRB assay
    		[PMID: 24956556]
    PC-3 IC50
    55.9 3
    Compound: AraC
    Cytotoxicity against human PC-3 cells
    Cytotoxicity against human PC-3 cells
    		[PMID: 38716896]
    PC-6 IC50
    50 6
    Compound: 2
    In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells
    In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells
    		[PMID: 2002478]
    PC-6 IC50
    50 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.
    In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.
    		[PMID: 1995905]
    PC-8 IC50
    0.28 6
    Compound: 2
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells
    		[PMID: 2002478]
    PC-8 IC50
    1.1 3
    Compound: ara-c
    Tested in vitro against PC-8 human lung adenocarcinoma
    Tested in vitro against PC-8 human lung adenocarcinoma
    		[PMID: 8277499]
    PC-9 IC50
    1.6 6
    Compound: 2
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells
    In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells
    		[PMID: 2002478]
    PC-9 IC50
    6.6 3
    Compound: ara-c
    Tested in vitro against PC-9 human lung adenocarcinoma
    Tested in vitro against PC-9 human lung adenocarcinoma
    		[PMID: 8277499]
    PC10 IC50
    > 100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.
    In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.
    		[PMID: 1995905]
    PC10 IC50
    > 100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.
    		[PMID: 1992123]
    PC10 IC50
    > 100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).
    In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).
    		[PMID: 3373480]
    QG-95 IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against QG-95 human squamous cell carcinoma
    Tested in vitro against QG-95 human squamous cell carcinoma
    		[PMID: 8277499]
    RPMI 6410 IC50
    6.0 x 10-6 41
    Compound: Ara-C
    Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines
    Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines
    		[PMID: 6827546]
    RS4-11 IC50
    0.26 3
    Compound: AraC
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    		[PMID: 20153646]
    SAOS-2 IC50
    2.7 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells
    In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells
    		[PMID: 2002478]
    SF-268 IC50
    7.68 x 10-3 3
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells by MTT assay
    Cytotoxicity against human SF268 cells by MTT assay
    		[PMID: 19345581]
    SF-268 IC50
    7.68 3
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    		[PMID: 20356655]
    SK-BR-3 IC50
    0.87 3
    Compound: ara-C
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    SK-ES1 IC50
    0.09 6
    Compound: 2
    In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells
    In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells
    		[PMID: 2002478]
    SK-HEP1 IC50
    1.8 3
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    SK-HEP1 IC50
    2.12 3
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    SK-MEL-28 IC50
    1 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells
    In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells
    		[PMID: 10780904]
    SK-MEL-28 IC50
    11.1 6
    Compound: Ara-C
    In vitro inhibitory activity against Human melanoma (P-36) cell line.
    In vitro inhibitory activity against Human melanoma (P-36) cell line.
    		[PMID: 1995905]
    SK-OV-3 IC50
    0.99 3
    Compound: ara-C
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    SMMC-7721 IC50
    0.013 3
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 29886320]
    SMMC-7721 IC50
    0.0271 3
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    		[PMID: 30852384]
    SNB-7 IC50
    1 3
    Compound: Ara-C
    In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1
    In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1
    		[PMID: 10780904]
    SNU-638 IC50
    0.15 3
    Compound: 1, ara-C
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    		[PMID: 19691349]
    SNU-638 IC50
    0.15 3
    Compound: 2, Ara-C
    Cytotoxicity against human SNU638 cells by SRB assay
    Cytotoxicity against human SNU638 cells by SRB assay
    		[PMID: 24956556]
    SNU-638 IC50
    0.15 3
    Compound: AraC
    Cytotoxicity against human SNU-638 cells
    Cytotoxicity against human SNU-638 cells
    		[PMID: 38716896]
    SNU-638 IC50
    1.08 3
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    		[PMID: 29906687]
    SNU-638 IC50
    3.98 3
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    		[PMID: 26010585]
    ST-KM-1 IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against ST-KM human stomach adenocarcinoma
    Tested in vitro against ST-KM human stomach adenocarcinoma
    		[PMID: 8277499]
    SW-620 IC50
    30 3
    Compound: Ara-C
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    		[PMID: 20211564]
    SW1573 IC50
    10500 3
    Compound: cytarabine
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    		[PMID: 17419604]
    SW48 IC50
    > 410 3
    Compound: ara-c
    Tested in vitro against SW-48 human colon adenocarcinoma
    Tested in vitro against SW-48 human colon adenocarcinoma
    		[PMID: 8277499]
    SW480 ED50
    3.42 6
    Compound: cytosine arabinoside
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    		[PMID: 1800632]
    SW480 IC50
    > 100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.
    In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.
    		[PMID: 1995905]
    SW480 IC50
    > 100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.
    		[PMID: 1992123]
    SW480 IC50
    > 100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).
    In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).
    		[PMID: 3373480]
    Small cell lung cancer cell line IC50
    > 100 3
    Compound: ara-C
    Compound was tested for the inhibition of small cell lung cancer
    Compound was tested for the inhibition of small cell lung cancer
    		[PMID: 3761322]
    T-24 IC50
    0.5 6
    Compound: 2
    In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells
    In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells
    		[PMID: 2002478]
    T-24 IC50
    0.5 6
    Compound: Ara-C
    In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.
    In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.
    		[PMID: 1995905]
    T-24 IC50
    > 100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.
    		[PMID: 1992123]
    T-24 IC50
    > 100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).
    In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).
    		[PMID: 3373480]
    T47D IC50
    2.7 3
    Compound: 1, ara-C
    Cytotoxicity against human T47D cells by sulforhodamine B method
    Cytotoxicity against human T47D cells by sulforhodamine B method
    		[PMID: 19691349]
    T47D IC50
    2.7 3
    Compound: AraC
    Cytotoxicity against human T47D cells
    Cytotoxicity against human T47D cells
    		[PMID: 38716896]
    T47D IC50
    2.72 3
    Compound: 2, Ara-C
    Cytotoxicity against human T47D cells by SRB assay
    Cytotoxicity against human T47D cells by SRB assay
    		[PMID: 24956556]
    TE-2 IC50
    > 100 6
    Compound: Ara-C
    In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.
    In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.
    		[PMID: 1995905]
    TE-2 IC50
    > 100 6
    Compound: ara-C
    Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.
    Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.
    		[PMID: 1992123]
    TE-2 IC50
    > 100 6
    Compound: ara-C
    In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).
    In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).
    		[PMID: 3373480]
    U-87MG ATCC CC50
    0.19 3
    Compound: 16
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    		[PMID: 35123007]
    U-87MG ATCC IC50
    0.85 3
    Compound: ara-C
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    U-87MG ATCC IC50
    2.88 3
    Compound: ara-C
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    U-937 IC50
    0.002 3
    Compound: Cytarabine
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    		[PMID: 30954427]
    U-937 IC50
    0.31 6
    Compound: ara-C
    Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.
    Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.
    		[PMID: 1992123]
    U-937 IC50
    0.46 6
    Compound: Ara-C
    In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.
    In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.
    		[PMID: 1995905]
    Vero CC50
    4.8 6
    Compound: Ara-C
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    		[PMID: 12444692]
    Vero EC50
    1.6 6
    Compound: Ara-C
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		[PMID: 12444692]
    Vero EC50
    3 6
    Compound: Ara-C
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		[PMID: 12444692]
    WI-38 IC50
    493.17 3
    Compound: CAR
    Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay
    		[PMID: 38516604]
    WI-38 IC50
    > 100 6
    Compound: CAR
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    		[PMID: 35963130]
    In Vitro

    Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM[1].
    Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cytarabine Related Antibodies
    In Vivo

    Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity[3].
    Cytarabine is highly effective against acute leukaemias, which causes the Cytarabine teristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    분자량

    243.22

    화학식

    C9H13N3O5
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N
    Structure Classification
    Initial Source

    Xerocomus nigromaculatus
    선적

    Room temperature in continental US; may vary elsewhere.
    보관
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    용액&용해도
    In Vitro: 

    DMSO : 17.3 mg/mL (71.13 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.1115 mL 20.5575 mL 41.1150 mL
    5 mM 0.8223 mL 4.1115 mL 8.2230 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • 몰농도 계산기

    • 농도 희석 계산기

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (411.15 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    순도&문서

    Purity: 99.98%

    SDS (557 KB)

    COA (252 KB) HNMR (260 KB) RP-HPLC (205 KB) LCMS (92 KB) Elemental Analysis Report (110 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [3]

    Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis.

    MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.1115 mL 20.5575 mL 41.1150 mL 102.7876 mL
    5 mM 0.8223 mL 4.1115 mL 8.2230 mL 20.5575 mL
    10 mM 0.4112 mL 2.0558 mL 4.1115 mL 10.2788 mL
    15 mM 0.2741 mL 1.3705 mL 2.7410 mL 6.8525 mL
    20 mM 0.2056 mL 1.0279 mL 2.0558 mL 5.1394 mL
    25 mM 0.1645 mL 0.8223 mL 1.6446 mL 4.1115 mL
    30 mM 0.1371 mL 0.6853 mL 1.3705 mL 3.4263 mL
    40 mM 0.1028 mL 0.5139 mL 1.0279 mL 2.5697 mL
    50 mM 0.0822 mL 0.4112 mL 0.8223 mL 2.0558 mL
    60 mM 0.0685 mL 0.3426 mL 0.6853 mL 1.7131 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cytarabine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cytarabine147-94-4Cytosine β-D-arabinofuranoside Cytosine Arabinoside Ara-CDNA/RNA SynthesisNucleoside Antimetabolite/AnalogHSVAutophagyEndogenous MetaboliteApoptosisOrthopoxvirusHerpes simplex virusInhibitorinhibitorinhibit

    최근 본 상품:

    온라인 문의

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Requested Quantity *

    고객명 *

    		 

    호칭

    메일주소 *

    		 

    전화번호 *

    Department

    		 

    회사명 *

    City

    도

    Country or Region *

    		      

    비고

    대량구매 문의

    Inquiry Information

    상품명:
    Cytarabine
    Cat. No.:
    HY-13605
    수량:
    MCE Japan Authorized Agent:

    고객리뷰

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Lot #

    고객명 *

    		 

    메일주소 *

    전화번호

    		 

    Department *

    회사명 *

    		 

    Country or Region *

    비고

    SAFETY DATA SHEET (SDS)

    English - EN (557 KB) Français - FR (557 KB) Deutsch - DE (557 KB) Norwegian - NO (557 KB) Español - ES (557 KB) Swedish - SV (557 KB) Italian - IT (557 KB) Korean - KR (557 KB) Portuguese - PT (557 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.